Competitive Therapies Are Plagued by Black Box Warnings 



Compare the Safety of Ultraviolet Phototherapy
vs. Biological Drugs Used for the Treatment
of Skin Disease

While biological drug therapies have become popular in the last few years, it is important to evaluate the safety of these medications. Every one of the following drugs has had numerous adverse effects and deaths where the drug was listed as the primary suspected cause.  

In contrast, Daavlin's phototherapy is an extremely safe and effective method of treatment. Even Oxsoralen, a drug used in conjunction with ultraviolet light to create PUVA, has an exemplary safety record. 

We invite you to view the statistics of our competitors. Click the links to read FDA statements and other related information. 


Adverse Effects:

Primary Suspect	2000-2001	2002-2003	2004-2005	2006-2007	Total:
Enbrel	10,721	2,633	4,254	21,140	38,748
Humira	23	4,112	9,851	6,573	20,559
Remicade	3,357	5,184	5,232	4,537	18,310
Methotrexate	633	888	779	284	2,584
Raptiva*	4	11	818	471	1,304*
Elidel	3	259	302	64	628
Protopic	70	50	103	79	302
Oxsoralen (PUVA)	3	0	0	0	3

Deaths:

Primary Suspect	2000-2001	2002-2003	2004-2005	2006-2007	Total:
Enbrel	510	344	227	311	1,392
Humira	6	130	520	347	1,003
Remicade	396	640	505	372	1,913
Methotrexate	109	122	120	36	387
Raptiva*	1	1	15	28	45*
Elidel	0	3	5	1	9
Protopic	0	5	0	0	5
Oxsoralen (PUVA)	0	0	0	0	0

*Although appearing to be the most innocuous of the biologic drugs in the comparison above; Raptiva was removed from the U.S. market on April 8, 2009 due to the risk of PML, a fatal brain infection.




   Data compiled using MedWatch statistics available at FDA.gov   




Enbrel is a registered trademark of Amgen, Inc. / Wyeth Pharmaceuticals.
Humira is a registered trademark of Abbott Laboratories.
Remicade is a registered trademark of Centocor, Inc.
Raptiva is a registered trademark of Genentech.
Elidel is a registered trademark of Novartis.
Protopic is a registered trademark of Astellas Pharma.